SUMMARY Normal brain function requires that the overall synaptic activity in neural circuits be kept constant. Long-term alterations of neural activity leads to homeostatic regulation of synaptic strength by a process known as synaptic scaling. The molecular mechanisms underlying synaptic scaling are largely unknown. Here we report that all-trans retinoic acid (RA), a well-known developmental morphogen, unexpectedly mediates synaptic scaling in response to activity blockade. We show that activity blockade increases RA synthesis in neurons, and that acute RA treatment enhances synaptic transmission. The RA-induced increase in synaptic strength is occluded by activity blockade-induced synaptic scaling. Suppression of RA synthesis prevents synaptic scaling. This novel form of RA signaling operates via a translation-dependent but transcription-independent mechanism, causes an up-regulation of postsynaptic glutamate receptor levels, and requires RARα receptors. Together, our data suggest that RA functions in homeostatic plasticity as a signaling molecule that increases synaptic strength by a protein synthesis-dependent mechanism.

No abstract

Neurexins are essential presynaptic cell-adhesion molecules that are linked to schizophrenia and autism, and are subject to extensive alternative splicing. Here, we used a novel genetic approach to test the physiological significance of neurexin alternative splicing. We generated knock-in mice in which alternatively spliced sequence #4 (SS4) of neurexin-3 is constitutively included, but can be selectively excised by cre-recombination. SS4 of neurexin-3 was chosen because it is highly regulated and controls neurexin-binding to neuroligins, LRRTMs, and other ligands. Unexpectedly, constitutive inclusion of SS4 in presynaptic neurexin-3 decreased postsynaptic AMPA- but not NMDA-receptor levels and enhanced postsynaptic AMPA-receptor endocytosis. Moreover, constitutive inclusion of SS4 in presynaptic neurexin-3 abrogated postsynaptic AMPA-receptor recruitment during NMDA-receptor-dependent LTP. These phenotypes were fully rescued by constitutive excision of SS4 in neurexin-3. Thus, alternative splicing of presynaptic neurexin-3 controls postsynaptic AMPA-receptor trafficking, revealing an unanticipated alternative splicing mechanism for trans-synaptic regulation of synaptic strength and long-term plasticity.

Heterozygous mutations of the NRXN1 gene, which encodes the presynaptic cell-adhesion molecule neurexin-1, were repeatedly associated with autism and schizophrenia. However, diverse clinical presentations of NRXN1 mutations in patients raise the question whether heterozygous NRXN1 mutations alone directly impair synaptic function. To address this question under conditions that precisely control for genetic background, we generated human ES cells with different heterozygous conditional NRXN1 mutations, and analyzed two different types of isogenic control and NRXN1-mutant neurons derived from these ES cells. Both heterozygous NRXN1 mutations selectively impaired neurotransmitter release in human neurons without changing neuronal differentiation or synapse formation. Moreover, NRXN1-mutant human neurons exhibited increased levels of CASK, a critical synaptic scaffolding protein that binds to neurexin-1. Our results show that, unexpectedly, heterozygous inactivation of NRXN1 directly impairs synaptic function in human neurons, and illustrate the value of this conditional deletion approach for studying the functional effects of disease-associated mutations.